Sgpharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 16-11-2024
- Paid Up Capital ₹ 0.50 M
as on 16-11-2024
- Company Age 20 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 2.20 M
as on 16-11-2024
- Revenue 2.20%
(FY 2023)
- Profit -10.12%
(FY 2023)
- Ebitda 25.43%
(FY 2023)
- Net Worth 6.51%
(FY 2023)
- Total Assets -18.47%
(FY 2023)
About Sgpharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.50 M.
The company has closed loans amounting to ₹2.20 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Bhavesh Bhagat and Chetan Bhagat serve as directors at the Company.
- CIN/LLPIN
U24230MH2004PTC146356
- Company No.
146356
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
17 May 2004
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Sgpharma Private Limited offer?
Sgpharma Private Limited offers a wide range of products and services, including TB, Tumor & Cancer Drugs, Antituberculosis Drug, Pharma Ingredients & Raw Materials, Anti Infective API, Medical Surgery & Treatment Centres, Medical Treatment Services.
Who are the key members and board of directors at Sgpharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Bhavesh Bhagat  | Director | 17-May-2004 | Current |
| Chetan Bhagat | Director | 17-May-2004 | Current |
Financial Performance of Sgpharma.
Sgpharma Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 2.2% increase. The company also saw a substantial fall in profitability, with a 10.12% decrease in profit. The company's net worth moved up by a moderate rise of 6.51%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sgpharma?
In 2023, Sgpharma had a promoter holding of 42.00% and a public holding of 58.00%. The company had 1 Subsidiary. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Sgpharma Global Private LimitedActive 4 years 1 monthBhavesh Bhagat and Chetan Bhagat are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 14 Nov 2016 | ₹1.00 M | Satisfied |
Others Creation Date: 28 Jun 2016 | ₹1.20 M | Satisfied |
How Many Employees Work at Sgpharma?
Sgpharma has a workforce of 26 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sgpharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sgpharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
